- Home
- THC vs DVA Comparison
THC vs DVA Comparison
Compare THC & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THC
- DVA
- Stock Information
- Founded
- THC 1967
- DVA 1994
- Country
- THC United States
- DVA United States
- Employees
- THC N/A
- DVA N/A
- Industry
- THC Hospital/Nursing Management
- DVA Misc Health and Biotechnology Services
- Sector
- THC Health Care
- DVA Health Care
- Exchange
- THC Nasdaq
- DVA Nasdaq
- Market Cap
- THC 11.7B
- DVA 10.9B
- IPO Year
- THC N/A
- DVA 1995
- Fundamental
- Price
- THC $167.86
- DVA $136.95
- Analyst Decision
- THC Buy
- DVA Hold
- Analyst Count
- THC 16
- DVA 4
- Target Price
- THC $184.50
- DVA $157.00
- AVG Volume (30 Days)
- THC 1.7M
- DVA 736.8K
- Earning Date
- THC 07-23-2025
- DVA 08-05-2025
- Dividend Yield
- THC N/A
- DVA N/A
- EPS Growth
- THC N/A
- DVA 14.90
- EPS
- THC 15.09
- DVA 10.11
- Revenue
- THC $20,520,000,000.00
- DVA $12,968,524,000.00
- Revenue This Year
- THC $2.22
- DVA $6.46
- Revenue Next Year
- THC $5.01
- DVA $3.24
- P/E Ratio
- THC $11.06
- DVA $13.41
- Revenue Growth
- THC N/A
- DVA 5.11
- 52 Week Low
- THC $109.82
- DVA $131.76
- 52 Week High
- THC $174.14
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- THC 58.77
- DVA 44.92
- Support Level
- THC $154.33
- DVA $134.64
- Resistance Level
- THC $170.27
- DVA $138.26
- Average True Range (ATR)
- THC 6.25
- DVA 2.71
- MACD
- THC -1.06
- DVA 0.14
- Stochastic Oscillator
- THC 70.90
- DVA 54.56
About THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 60 as of December 2023) and over 450 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.